In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States
Abstract
Background: Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are intrinsically multidrug-resistant pathogens that cause chronic pulmonary infections in individuals with cystic fibrosis (CF) and severe infections in other vulnerable populations. Therapeutic options remain limited as resistance to commonly used agents continues to emerge.
Objectives: To evaluate the in vitro activity of cefiderocol against a collection of Bcc and B. gladioli isolates from individuals with CF in the USA and to compare these findings with historical susceptibility data for 16 other antimicrobial agents.
Methods: A total of 150 clinical isolates representing multiple Bcc species and B. gladioli were tested. Cefiderocol MICs were determined using iron-depleted broth microdilution (ID-BMD) and iron-depleted agar dilution (ID-AD). Species-specific MIC distributions were assessed, and cefiderocol activity was compared with historical MIC data for 16 other antimicrobial agents previously tested against the same isolate panel. Mechanistic studies evaluated blaPenA expression and hydrolysis of cefiderocol by purified PenA1.
Results: Cefiderocol MIC50 and MIC90 values were 0.06 and 8 mg/L, and 0.03 and 8 mg/L, respectively, by both ID-BMD and ID-AD. Low MIC90 values were observed for Burkholderia cenocepacia, B. cepacia, B. gladioli, and most ‘other Bcc’ species, whereas elevated MIC90 values were detected for Burkholderia multivorans and Burkholderia vietnamiensis. Cefiderocol demonstrated the lowest MIC50 values when compared with historical data for 16 other agents; did not induce blaPen expression; and was not hydrolysed by purified PenA1.
Conclusions: Cefiderocol demonstrated broad in vitro activity against Bcc and B. gladioli isolates from individuals with CF and showed stability against key β-lactamase-mediated resistance mechanisms.
Related
- In Vitro Activity of Eravacycline, Aztreonam-Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital.
- Genome mining, antibacterial activity, and metabolomic profiling reveal the biosynthetic potential of Burkholderia glumae isolates from Thailand with activity against clinically important bacterial pathogens
- In Vitro Activity of Aztreonam-Avibactam, Cefiderocol, and Conventional Antimicrobials Against Metallo-β-Lactamase-Producing Gram-Negative Urinary Isolates: A Systematic Review and Local Single-Center Retrospective Evaluation in a Tertiary Care Hospital (2016-2025) and Evaluation of Novel Agents (2021-2025).
- Clinical characteristics, molecular features and in vitro susceptibility to sulbactam-durlobactam, cefiderocol, and eravacycline in NDM-1-producing versus OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates from children in Guangxi, China.
- Genomic and morphological analysis of human clinical Burkholderia pseudomallei isolates from New Caledonia (2021−2022)
BibTeX
@article{mojica2026vitro,
title = {{In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States}},
author = {Maria F Mojica and Elise T Zeiser and Scott A Becka and Lindsay J Caverly and John J Lipuma and Robert A Bonomo and Krisztina M Papp-Wallace},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
month = oct,
doi = {10.1093/jac/dkag347},
url = {https://doi.org/10.1093/jac/dkag347},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States
AU - Maria F Mojica
AU - Elise T Zeiser
AU - Scott A Becka
AU - Lindsay J Caverly
AU - John J Lipuma
AU - Robert A Bonomo
AU - Krisztina M Papp-Wallace
PY - 2026
DA - 2026/10/27
JO - Journal of Antimicrobial Chemotherapy
DO - 10.1093/jac/dkag347
UR - https://doi.org/10.1093/jac/dkag347
AB - Background: Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are intrinsically multidrug-resistant pathogens that cause chronic pulmonary infections in individuals with cystic fibrosis (CF) and severe infections in other vulnerable populations. Therapeutic options remain limited as resistance to commonly used agents continues to emerge. Objectives: To evaluate the in vitro activity of cefiderocol against a collection of Bcc and B. gladioli isolates from individuals with CF in the USA and to compare these findings with historical susceptibility data for 16 other antimicrobial agents. Methods: A total of 150 clinical isolates representing multiple Bcc species and B. gladioli were tested. Cefiderocol MICs were determined using iron-depleted broth microdilution (ID-BMD) and iron-depleted agar dilution (ID-AD). Species-specific MIC distributions were assessed, and cefiderocol activity was compared with historical MIC data for 16 other antimicrobial agents previously tested against the same isolate panel. Mechanistic studies evaluated blaPenA expression and hydrolysis of cefiderocol by purified PenA1. Results: Cefiderocol MIC50 and MIC90 values were 0.06 and 8 mg/L, and 0.03 and 8 mg/L, respectively, by both ID-BMD and ID-AD. Low MIC90 values were observed for Burkholderia cenocepacia, B. cepacia, B. gladioli, and most ‘other Bcc’ species, whereas elevated MIC90 values were detected for Burkholderia multivorans and Burkholderia vietnamiensis. Cefiderocol demonstrated the lowest MIC50 values when compared with historical data for 16 other agents; did not induce blaPen expression; and was not hydrolysed by purified PenA1. Conclusions: Cefiderocol demonstrated broad in vitro activity against Bcc and B. gladioli isolates from individuals with CF and showed stability against key β-lactamase-mediated resistance mechanisms.
SN - 0305-7453
SN - 1460-2091
ER -